Projectdetails
Doel van het project
P-PEAKS is a multicenter, intercontinental Phase II randomized controlled trial evaluating the safety, efficacy, and feasibility of personalized bacteriophage therapy in combination with intravenous beta-lactam antibiotics for the secondary prevention of recurrent urinary tract infections (rUTIs) caused by Escherichia coli in female patients. The project aims to deliver an improved, effective and meaningful solution for the prevention of recurrent UTIs in female patients improving their health outcomes and quality of life.
Rol van de instelling
Partner beneficiary in charge of the phage production and testing.
Financieringsbron
This project is co-financed by the Horizon Europe program (Grant number: 101289070).
| Korte titel | Personalized-Phage Against E. Coli with IV Antibiotic to Knockout Stable Biofilms in Urinary Tract Infections |
|---|---|
| Acroniem | P-PEAKS UTI |
| Status | Niet gestart |
| Effectieve start/einddatum | 1/06/26 → 31/05/30 |
Samenwerkende partners
- Koninklijke Militaire School
- Unity Health Toronto (hoofd)
- TARTU ULIKOOL
- HADASSAH MEDICAL ORGANIZATION
- Assistance Publique - Hôpitaux de Paris
- FUNDACION PUBLICA GALEGA DE INVESTIGACION BIOMEDICA INIBIC
- The Hebrew University of Jerusalem
- University College London
- Lund University
- University of Calgary
- UNIVERSITE LAVAL
- Europaischer Nierenpatientenverband
- AZIENDA OSPEDALIERO UNIVERSITARIA PISANA
- Mayo Clinic
- FAGOTERAPIA LAB S.R.L.
- SIHTASUTUS TARTU ULIKOOLI KLIINIKUM
- BAYLOR COLLEGE OF MEDICINE
- PHILIPPS UNIVERSITAET MARBURG
- MICRON RESEARCH LIMITED
- THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
- QEEN BIOTECHNOLOGIES INC.
Vingerafdruk
Verken de onderzoeksgebieden die bij dit project aan de orde zijn gekomen. Deze labels worden gegenereerd op basis van de onderliggende prijzen/beurzen. Samen vormen ze een unieke vingerafdruk.